Pharmacokinetic analysis of new anti-inflammatory drugs: Clinical trials and results

Read full text Summarise with VIRAT
Authors: Willem van der Berg, Marieke de Vries
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Roughly 1.7 billion people worldwide live with musculoskeletal conditions that demand long-term anti-inflammatory therapy, yet the pharmacokinetic profiles of many newer agents remain incompletely characterized [1]. This research presents a detailed pharmacokinetic analysis of five novel anti-inflammatory compounds evaluated across two phase II clinical trials conducted at academic medical centers in the Netherlands between January 2021 and December 2022. A total of 312 participants with moderate-to-severe rheumatoid arthritis were enrolled and randomized to receive one of the five investigational compounds or celecoxib as an active comparator. Blood samples were collected at 14 predetermined time points over 72 hours following single-dose oral administration, and plasma drug concentrations were determined using validated LC-MS/MS methods. Compound NL-347, a selective COX-2 inhibitor with a novel pyrrolidine scaffold, demonstrated the most favorable pharmacokinetic profile among all candidates. It achieved a peak plasma concentration of 1243.6 ng/mL at 1.4 hours post-dose, with an area under the concentration-time curve of 9187.4 ng•h/mL and oral bioavailability of 84.1%. Its elimination half-life of 11.2 hours supports once-daily dosing, a notable advantage over celecoxib which showed a half-life of 7.4 hours in our cohort. Compound NL-519 also performed well, recording bioavailability of 78.6% and a half-life of 9.8 hours with rapid absorption (Tmax 1.8 hours). By contrast, compounds NL-482 and NL-638 exhibited lower bioavailability (58.9% and 46.3% respectively), possibly due to extensive first-pass hepatic metabolism confirmed through in vitro microsomal assays. Adverse events were predominantly mild gastrointestinal complaints occurring in 31.4% of participants, consistent with the class effect of anti-inflammatory agents. Hepatic enzyme elevation appeared in 14.2% of subjects receiving NL-638, prompting dose-adjustment recommendations for future trials. No serious cardiovascular events were recorded during the observation period. Population pharmacokinetic modeling using NONMEM software identified body weight and CYP2C9 genotype as significant covariates influencing drug clearance, with poor metabolizers showing 37.8% lower clearance rates than extensive metabolizers. These results position NL-347 and NL-519 as leading candidates for phase III evaluation, while NL-482 and NL-638 require reformulation to address bioavailability limitations before further clinical development can proceed.

Fields of Study & Subjects

Inflammatory mediators and NSAID effects Rheumatoid Arthritis Research and Therapies Pharmacogenetics and Drug Metabolism

Publication details

Journal / source
International Journal of Pharmacology and Clinical Research
Volume
8
Issue
2
Pages
87–93
Publication date
1 February 2026
Language
EN